Clinical application study on miR-98–5p as a prognostic biomarker in hepatocellular carcinoma

Pengtian, JI; Wang, Xiaoyan

doi:10.1016/j.clinre.2023.102077

Cited by 6 publications

(5 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, upregulated miR-192-5p promotes survival and suppresses apoptosis by repressing PABPC4 [30]. Our results reflect multiple miRNAs that might influence apoptosis in the HBV-HCC continuum including miR-199a-3p [168][169][170][171][172][173][174][175][176][177][178], miR-584-5p [179][180][181][182], miR-98-5p [154][155][156][157][158], miR-454-3p [183][184][185][186], miR-4516 [187,188] and miR-483-3p [20,21], but further investigation should validate this.…”

Section: Discussionmentioning

confidence: 62%

“…Conversely, upregulated miR-483-5p inhibits cell proliferation and fibrosis by targeting PPARα and TIMP2 [34]. Other miRNAs in our results that might modulate cell proliferation in HBV-HCC include miR-874-3p [141], miR-451a [142][143][144][145][146][147], miR-182-5p [148][149][150][151][152][153], miR-98-5p [154][155][156][157][158], miR-363-3p [159][160][161][162] and miR-339-3p [163][164][165].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Serum microRNA Profiles and Pathways in Hepatitis B-Associated Hepatocellular Carcinoma: A South African Study

Sartorius,

Winkler

et al. 2024

IJMS

View full text Add to dashboard Cite

The incidence and mortality of hepatocellular carcinoma (HCC) in Sub-Saharan Africa is projected to increase sharply by 2040 against a backdrop of limited diagnostic and therapeutic options. Two large South African-based case control studies have developed a serum-based miRNome for Hepatitis B-associated hepatocellular carcinoma (HBV-HCC), as well as identifying their gene targets and pathways. Using a combination of RNA sequencing, differential analysis and filters including a unique molecular index count (UMI) ≥ 10 and log fold change (LFC) range > 2: <−0.5 (p < 0.05), 91 dysregulated miRNAs were characterized including 30 that were upregulated and 61 were downregulated. KEGG analysis, a literature review and other bioinformatic tools identified the targeted genes and HBV-HCC pathways of the top 10 most dysregulated miRNAs. The results, which are based on differentiating miRNA expression of cases versus controls, also develop a serum-based miRNA diagnostic panel that indicates 95.9% sensitivity, 91.0% specificity and a Youden Index of 0.869. In conclusion, the results develop a comprehensive African HBV-HCC miRNome that potentially can contribute to RNA-based diagnostic and therapeutic options.

show abstract

Section: Discussionmentioning

confidence: 62%

Section: Discussionmentioning

confidence: 99%

Serum microRNA Profiles and Pathways in Hepatitis B-Associated Hepatocellular Carcinoma: A South African Study

Sartorius,

Winkler

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

“…6A and Table S2 ). To cross-check the accuracy of the RNA-seq results, qRT-PCR analysis was conducted on eight differentially expressed genes (DEGs), including four genes involved in cell proliferation, invasion and migration ( FOS , PDE6G , RGS16 and HBEGF ) ( MildeLangosch, 2005 ; Nikolova et al, 2010 ; Carper et al, 2014 ; Bakiri et al, 2017 ; Hu et al, 2020 ; Ji & Wang, 2023 ; Zhang et al, 2023 ) and four genes related to oxidative stress, DNA damage and apoptosis ( ATF3 , DDIT4 , SOCS1 and MXD1 ) ( Hai et al, 1999 ; Kim, Kim & Lee, 2020 ; Ding et al, 2021 ; Ryu et al, 2022 ; Xiong et al, 2022 ; Shao et al, 2023 ) ( Fig. 6D ).…”

Section: Resultsmentioning

confidence: 99%

Phenethyl isothiocyanate inhibits the carcinogenic properties of hepatocellular carcinoma Huh7.5.1 cells by activating MAPK/PI3K-Akt/p53 signaling pathways

Du,

Zhang,

Chen

et al. 2024

PeerJ

View full text Add to dashboard Cite

Background Hepatocellular carcinoma (HCC) is an aggressive malignancy with limited effective treatment options. Phenethyl isothiocyanate (PEITC) is a bioactive substance present primarily in the cruciferous vegetables. PEITC has exhibited anti-cancer properties in various cancers, including lung, bile duct, and prostate cancers. It has been demonstrated that PEITC can inhibit the proliferation, invasion, and metastasis of SK-Hep1 cells, while effectively inducing apoptosis and cell cycle arrest in HepG2 cells. However, knowledge of its anti-carcinogenic effects on Huh7.5.1 cells and its underlying mechanism remains elusive. In the present study, we aim to evaluate the anti-carcinogenic effects of PEITC on human HCC Huh7.5.1 cells. Methods MTT assay and colony formation assay was performed to investigate the anti-proliferative effects of PEITC against Huh7.5.1 cells. The pro-apoptosis effects of PEITC were determined by Annexin V-FITC/PI double staining assay by flow cytometry (FCM), mitochondrial transmembrane potential (MMP) measurement, and Caspase-3 activity detection. A DAPI staining and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay was conducted to estimate the DNA damage in Huh7.5.1 cells induced by PEITC. Cell cycle progression was determined by FCM. Transwell invasion assay and wound healing migration assay were performed to investigate the impact of PEITC on the migration and invasion of Huh7.5.1 cells. In addition, transcriptome sequencing and gene set enrichment analysis (GSEA) were used to explore the potential molecular mechanisms of the inhibitory effects of PEITC on HCC. Quantitative real-time PCR (qRT-PCR) analysis was performed to verify the transcriptome data. Results MTT assay showed that treatment of Huh7.5.1 cells with PEITC resulted in a dose-dependent decrease in viability, and colony formation assay further confirmed its anti-proliferative effect. Furthermore, we found that PEITC could induce mitochondrial-related apoptotic responses, including a decrease of mitochondrial transmembrane potential, activation of Caspase-3 activity, and generation of intracellular reactive oxygen species. It was also observed that PEITC caused DNA damage and cell cycle arrest in the S-phase in Huh7.5.1 cells. In addition, the inhibitory effect of PEITC on the migration and invasion ability of Huh7.5.1 cells was assessed. Transcriptome sequencing analysis further suggested that PEITC could activate the typical MAPK, PI3K-Akt, and p53 signaling pathways, revealing the potential mechanism of PEITC in inhibiting the carcinogenic properties of Huh7.5.1 cells. Conclusion PEITC exhibits anti-carcinogenic activities against human HCC Huh7.5.1 cells by activating MAPK/PI3K-Akt/p53 signaling pathways. Our results suggest that PEITC may be useful for the anti-HCC treatment.

show abstract

“…67 most HCC patients. 71 TGF-β1 overexpression is related to the prognosis and progression of HCC. 72 TGF-β1 promotes CTLA-4 and PD-1 expression on T lymphocytes but reduces T lymphocyte cytotoxicity against HCC cells.…”

Section: The Regulation Of Ctla-4 Signals In the Development Of Hccmentioning

confidence: 99%

“…TGF‐β1 is a cytokine secreted by malignant hepatocytes and inflammatory cells that is overexpressed in most HCC patients 71 . TGF‐β1 overexpression is related to the prognosis and progression of HCC 72 .…”

Section: The Regulatory Signals Of Icp In the Development Of Hccmentioning

confidence: 99%

Blockade of PD‐1 and CTLA‐4: A potent immunotherapeutic approach for hepatocellular carcinoma

Hou,

Xu,

et al. 2023

BioFactors

View full text Add to dashboard Cite

Immune checkpoints (ICPs) can promote tumor growth and prevent immunity‐induced cancer cell apoptosis. Fortunately, targeting ICPs, such as programmed cell death 1 (PD‐1) or cytotoxic T lymphocyte associated protein 4 (CTLA‐4), has achieved great success in the past few years and has gradually become an effective treatment for cancers, including hepatocellular carcinoma (HCC). However, many patients do not respond to ICP therapy due to acquired resistance and recurrence. Therefore, clarifying the specific mechanisms of ICP in the development of HCC is very important for enhancing the efficacy of anti‐PD‐1 and anti‐CTLA‐4 therapy. In particular, antigen presentation and interferon‐γ (IFN‐γ) signaling were reported to be involved in the development of resistance. In this review, we have explained the role and regulatory mechanisms of ICP therapy in HCC pathology. Moreover, we have also elaborated on combinations of ICP inhibitors and other treatments to enhance the antitumor effect. Collectively, recent advances in the pharmacological targeting of ICPs provide insights for the development of a novel alternative treatment for HCC.

show abstract

Clinical application study on miR-98–5p as a prognostic biomarker in hepatocellular carcinoma

Cited by 6 publications

References 24 publications

Serum microRNA Profiles and Pathways in Hepatitis B-Associated Hepatocellular Carcinoma: A South African Study

Serum microRNA Profiles and Pathways in Hepatitis B-Associated Hepatocellular Carcinoma: A South African Study

Phenethyl isothiocyanate inhibits the carcinogenic properties of hepatocellular carcinoma Huh7.5.1 cells by activating MAPK/PI3K-Akt/p53 signaling pathways

Blockade of PD‐1 and CTLA‐4: A potent immunotherapeutic approach for hepatocellular carcinoma

Contact Info

Product

Resources

About